Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Rhea-AI Summary

Cybin Inc. (NYSE American:CYBN) has announced a conference call and webcast scheduled for November 18, 2024, at 8:00 a.m. ET. The presentation will feature 12-month efficacy and safety data from the company's Phase 2 study of CYB003 in Major Depressive Disorder, along with details about the recently initiated Phase 3 PARADIGM program. The event will be led by CEO Doug Drysdale and CMO Amir Inamdar, followed by a Q&A session for investors.

Positive

• Phase 2 study of CYB003 has reached 12-month milestone with data ready for presentation
• Company has progressed to Phase 3 PARADIGM program for CYB003

Negative

• None.

- Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 -

- Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 -

TORONTO--(BUSINESS WIRE)-- Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET.

The event will be hosted by Cybin’s Chief Executive Officer, Doug Drysdale, and Cybin’s Chief Medical Officer, Amir Inamdar, and will include presentation of 12-month efficacy and safety data from the Company’s Phase 2 study of CYB003 in Major Depressive Disorder and an overview of the design of its recently initiated Phase 3 PARADIGM^™ program in CYB003. A Q&A session for the investment community will follow the prepared remarks.

Conference Call and Webcast Details:

Date:		Monday, November 18, 2024
Time:		8:00 a.m. ET.
Dial-in:		800-579-2543 (U.S. Toll-Free) or 785-424-1789 (International)
Conference ID:		CYBN1118
Webcast:		Register for the webcast here

The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

About Cybin

Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.

With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, in Phase 3 development for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.

Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.

Cautionary Notes and Forward-Looking Statements

Certain statements in this news release relating to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company’s plans to present 12-month efficacy and safety results from its Phase 2 study of CYB003; provide an overview of the design of its PARADIGM program; and the Company’s plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the spread of a pandemic on the Company's operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in each of the Company's management's discussion and analysis for the three and six month periods ended September 30, 2024 and the Company’s annual information form for the year ended March 31, 2024, which are available under the Company's profile on www.sedarplus.ca and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

Neither the Cboe Canada nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114386704/en/

Investor & Media:

Gabriel Fahel

Chief Legal Officer

Cybin Inc.

1-866-292-4601

irteam@cybin.com – or – media@cybin.com

Source: Cybin Inc.

FAQ

When will Cybin (CYBN) present its 12-month Phase 2 data for CYB003?

Cybin will present the 12-month Phase 2 data for CYB003 on November 18, 2024, at 8:00 a.m. ET during a conference call and webcast.

What will be discussed in Cybin's (CYBN) November 18 presentation?

The presentation will cover 12-month efficacy and safety data from the Phase 2 study of CYB003 in Major Depressive Disorder and provide an overview of the Phase 3 PARADIGM program design.

Has Cybin (CYBN) started its Phase 3 trials for CYB003?

Yes, Cybin has recently initiated its Phase 3 PARADIGM program for CYB003, which will be discussed during the November 18, 2024 presentation.